{"title": "PDF", "author": "PDF", "url": "https://core.ac.uk/download/pdf/81924168.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " VALUE IN HEALTH 18 (2015) A805\u2013A881  A871\nfemales in Mexico. The model compared baseline coverage of 70% for two doses of \nthe quadrivalent vaccine versus bivalent vaccine. Mexico specific data was used from literature where available; default values were used otherwise. Input data included demographic, behavioral, epidemiological and screening parameters, and direct treatment costs of HPV-related morbidities from a public health perspec-tive.\n R\nesults:  In a 100-year period, as compared to a two dose 70% bivalent vac-\ncination program, a 70% quadrivalent vaccination program coverage would result in reductions of HPV 6/11-related disease incidence at the population level as follows: genital warts in females (83%), genital warts in males (81.4%) and HPV6/11-related CIN1 (82%) . This would translate into a reduction of HPV 6/11-related disease cost of 59.1%, 56.3%, and 55.7% for genital warts among females, genital warts among males, and HPV6/11-related CIN1, respectively. Under the model assumptions, over a 100 year period, the total HPV6/11/16/18- related disease costs avoided would be over $1.7 billion Mexican Pesos. Thesincremental cumulative QALYs gained per 100,000 by HPV 6/11/16/18-related disease over 100 years would be 30.31 when com-pared with an HPV16/18 vaccination program.\n Con\nC\nlusions: In Mexico, routine \nvaccination of 9-11 year old females with a quadrivalent HPV6/11/16/18 vaccine has incremental economic, public health, and humanistic impact as compared to a bivalent HPV 16/18 vaccine\nPIN21\nAssess\nIN\ng the Publ\nI\nc \nh\ne\nA\nlth Im\nPAct AN\nd \nc\nost \ne\nffect\nI\nve\nN\ness of \nP\nN\neumococc A\nl v\nAcc\nIN\nes for Adults 65 Ye\nA\nrs of Age \nIN\n \nc\nolomb\nIA\nYang HK1, Dasbach EJ2, Guarin D3, Hernandez G4, Lemos E4\n1Merck & Co., Inc, West Point, PA, USA, 2Merck & Co. Inc, North Wales, PA, USA, 3Merck Sharp & \nDohme, Bogota, Colombia, 4MSD Colombia, Bogota, Colombia\nobjeCtives: Recently published efficacy data for 13-valent pneumococcal conju-\ng\nate vaccine (PCV13) and 23-valent pneumococcal polysaccharide vaccine (PPSV23) \nprovides an opportunity to update prior economic evaluations of pneumococcal vaccination in Colombia. This study aims to examine the public health impact and cost-effectiveness of PPSV23 versus PCV13 to prevent adult pneumococcal diseases in Colombia.\n Methods:\n We applied an economic model that incorpo -\nrated costs, health outcomes, and quality-adjusted life-year losses associated with invasive pneumococcal disease (IPD) and non-bacteremic pneumococcal pneumonia (NBPP) in a cohort of 65-year-old adults in Colombia. From the payers perspective, we evaluated the public health impact and cost-effectiveness of three strategies: no vaccination, PPSV23, PCV13. Vaccine effectiveness was based on recently published efficacy data and vaccine costs were based on the 2015 PAHO (Pan American Health Organization) reported price. All other costs and utilities were based on literature.\n R\nesults:  PPSV23 was more effective than PCV13 in \nreducing pneumococcal disease and the associated costs in 65-year-old adults in Colombia. Specifically, PPVSV23 reduced IPD cases by 20.0%, NBPP cases by 12.4%, IPD deaths by 16.5%, and NBPP deaths by 10.3%; PVC13 reduced IPD cases by 17.0%, NBPP cases by 9.8%, IPD deaths by 14.8%, and NBPP deaths by 8.6% (all versus no vaccination). From an economic perspective, both PPSV23 and PCV13 were cost-saving relative to no vaccination. However, vaccinating adults with PPSV23 reduced costs more than PCV13. The most influential parameters in the analysis were vac-cine effectiveness against NBPP and the duration of vaccine protection. PPSV23 is a less costly and more effective vaccination strategy than PCV13 when the degree of vaccine protection for PPSV23 against NBPP is greater than 30% and the dura-tion of vaccine protection is the same.\n Con\nC\nlusions: PPSV23 is a more effec-\ntive and less costly vaccination strategy than PCV13 for adults 65 years of age in  \nColombia.\nPIN22\ne\nco\nN\nom\nI\nc \ne\nvA\nluAt\nI\no\nN\n of \ne\nrtAP\ne\nN\nem \nIN\n the t\nre\nAtme\nN\nt of I\nN\ntr\nA\n-\nAbdom\nINA\nl I\nN\nfect\nI\no\nN\ns, from the Pers\nP\nect\nI\nve of Imss\nreyes-Lopez A\nHospital Infantil de M\u00e9xico \u201cFederico Gomez\u201d, Mexico, Mexico\nobjeCtives: Conduct a cost effectiveness analysis of ertapenem in the treatment \nof moder\nate community acquired intra-abdominal infections, from the Instituto \nMexicano del Seguro Social (IMSS) perspective.  Methods:\n Cost-effectiveness \nanalysis from the IMSS perspective based on a decision analytic model of hypo-\nthetical cohorts. Target population was patients over 15 years covered by IMSS with moderate community acquired intra-abdominal infection caused by E. coli. The time horizon was one year. Response parameters used were obtained from literature and cost inputs were obtained from IMSS\u00b4DRGs. A univariate sensitivity analysis was performed\n Resul\nts: Total costs of treatment were $24,912.84 MXP \nfor ertapenem, $31,609.52 MXP for meropenem, $32,705.57 for ceftazidime/metro-nidazole, $32,808.58 for ceftriaxone/metronidazole, $36,335.15 MXP for levofloxacin/metronidazole and $36,588.39 MXP for ciprofloxacin/metronidazole. Compared to ertapenem, savings ranged from $11,676 MXP for ciprofloxacin/metronidazole to $6,697 MXP for meropenem. Ertapenem as a first line treatment option in moderate community acquired intra-abdominal infection has the lowest treatment cost and has the best success therapeutic rate.\n Con\nC\nlusions: Ertapenem is a dominant \ncost-effective and cost-saving alternative for the treatment of moderate community acquired intra-abdominal infection.\nPIN23\nc\nosto-\ne\nfect\nI\nv\nI\ndA\nd \nd\ne \nlA\n v\nAcu\nNA\n \nc\no\nN\ntr\nA\n \ne\nl \nd\ne\nN\ngue 2014\nCastro Rodriguez R1, Rueda-Gallardo JA1, Avella Ni\u00f1o MF1, Lopez JG2, Caicedo Navas AG3\n1Universidad de los Andes, Bogota D.C, Colombia, 2Sanofi Pasteur, Mexico City, Mexico, 3Sanofi \nPasteur, Bogota, Colombia\nobjeCtivos: El dengue es considerado como una enfermedad de inter\u00e9s p\u00fablico en \nl\nos pa\u00edses de \u00e1reas tropicales y sub-tropicales. El objetivo de este estudio es evaluar \npara Colombia el impacto de una vacuna tetravalente contra el dengue, mediante \nun an\u00e1lisis costo-efectividad calculando la carga de la enfermedad a partir de DALYs.\n Met\nodolog\u00ed\nA\ns: Desarollo de un modelo para evaluar el an\u00e1lisis del costo \nefectividad incorporando la protecci\u00f3n indirecta y con ajuste por el nivel de subregistro  848 y 564 muertes en el escenario m\u00e1s y menos optimista, respectivamente. Del mismo modo, PCV10 evitar\u00edan entre 498 y 403 muertes.\n Con\nC\nlusiones: PCV13 y \nPCV10 son estrategias costo-ahorradoras frente a no vacunar .PCV10 fue dominada frente a PCV-13 en los escenarios m\u00e1s optimistas de ambas vacunas. La raz\u00f3n de costo-efectividad incremental fue USD$ 1.863 /AVG para PCV-13 comparada con PCV10 en los escenarios menos optimistas de ambas vacunas.\nPIN18\ne\nvA\nluAc\nI\n\u00f3\nN\n de \nc\nosto \ne\nfect\nI\nv\nI\ndA\nd de \nd\nolutegr\nAv\nI\nr (dtg) v\ns \nrA\nltegr\nAv\nI\nr (\nrA\nl) \neN\n \ns\negu\nN\ndA\n \nl\n\u00ed\nN\ne\nA\n de t\nr\nAtA\nm\nI\ne\nN\nto e\nN\n PAc\nI\ne\nN\ntes \nc\no\nN \nvI\nh e\nN\n \nc\nolomb\nIA\nVelandia D1, Gomez JM2, Vivas S1\n1Centro de Estudios e Investigaci\u00f3n en Salud de la Fundaci\u00f3n Santa Fe de Bogot\u00e1, Bogot\u00e1, \nColombia, 2Fundaci\u00f3n Santa Fe de Bogot\u00e1, Bogot\u00e1, Colombia\nobjeCtivos: Evaluar la costo-efectividad de Dolutegravir(DTG) frente a \nRalte\ngravir(RAL), en segunda l\u00ednea de tratamiento antirretroviral para la \npoblaci\u00f3n Colombiana con VIH mayor a 18 a\u00f1os y v\u00edrgenes a Inhibidores de \nIntegrasa(INI).  Met\nodolog\u00ed\nA\ns: Se utiliz\u00f3 la t\u00e9cnica de Simulaci\u00f3n de Montecarlo \nen un modelo de Markov que describe la evoluci\u00f3n cl\u00ednica de pacientes con VIH en 12 estados de salud, 6 de ellos relacionados con VIH directamente (VIH cr\u00f3nico con/sin infecci\u00f3n oportunista) y los otros asociados al desarrollo o no de una enferme-dad cardiovascular, ECV. El modelo se utiliz\u00f3 anteriormente en Canad\u00e1 y se adapt\u00f3 con informaci\u00f3n epidemiol\u00f3gica y de costos para Colombia. La perspectiva es la del tercer pagador para toda la esperanza de vida con tasa de descuento de 5% en costos y resultados. Se explor\u00f3 la influencia de la incertidumbre mediante la curva de aceptabilidad por bootstrapping-no-param\u00e9trico de 1,000 replicaciones y an\u00e1lisis de sensibilidad de una sola v\u00eda en los par\u00e1metros de inter\u00e9s. Se emple\u00f3 la Cohorte del estudio cl\u00ednico SAILING (n=\n \n710).  R\nesult Ad\nos: Los costos totales para \nlos pacientes tratados con DTG fueron USD$157,996.65 y USD$158,722.92 con RAL. Los costos incrementales estimados fueron -USD$726.28 y la ganancia incremental en a\u00f1os de vida ajustados por calidad, AVAC\u2019s, fue de 0.277 AVAC\u2019s (3.32 meses). El RICE calculado fue -USD$/AVAC 2,625.22( <\n 1\n PIBper-c\u00e1pita colombiano). La curva \nde aceptabilidad muestra bajo nivel de incertidumbre, toda la densidad estimada involucra ahorro en costos y ganancias en salud. El modelo es sensible a reducciones en la tasa de descuento de costos y resultados, con tasa de 0%, el RICE se ubica entre 1 y 3 PIB per c\u00e1pita, es decir DTG pasa a ser potencialmente costo efectiva. Modificaciones en utilidades, costos de ECV, muerte, backbone u horizonte temporal no modifica lo resultados base.\n Con\nC\nlusiones: DTG es costo efectivo frente a RAL \ncon un nivel bajo de incertidumbre.\nPIN19\nA\nNA\nl\nI\ns\nI\ns de \nc\nosto \ne\nfect\nI\nv\nI\ndA\nd Y\n \nc\nosto \nu\nt\nI\nl\nI\ndA\nd del uso de \nd\nAcl\nAtA\nsv\nI\nr+Asu\nNAP\nrev\nI\nr e\nN\n el t\nr\nAtA\nm\nI\ne\nN\nto de P Ac\nI\ne\nN\ntes \nc\no\nN \nh\ne\nPAt\nI\nt\nI\ns \nc\n e\nN\n \nc\nolomb\nIA\n, \nd\nesde \nlA\n Pers\nP\nect\nI\nvA\n \nd\nel t\nercer P Ag\nA\ndor\nMarrugo Figueroa RD, Romero Prada ME, Acero Acero G, Alfonso Qui\u00f1ones PA\nFundaci\u00f3n Salutia, Bogot\u00e1, Colombia\nobjeCtivos: Analizar la relaci\u00f3n de costo efectividad del uso de \ndaclatasvir\n+asunaprevir frente a peginterfer\u00f3n alfa+ Ribaivirina m\u00e1s telaprevir \no boceprevir para el tratamiento de hepatitis C en Colombia\n M\netodolog\u00ed As\n: \nModelo de Markov, tipo costo-efectividad desde la perspectiva del tercer pagador, \nen un horizonte temporal hasta la muerte, bajo ciclos anuales, con una cohorte hipot\u00e9tica de 100 pacientes con edad media de 50-57 a\u00f1os. Se simula la historia natural de la enfermedad y sus complicaciones, pasando de estados de cirrosis compensada, descompensada, carcinoma hepatocelular, trasplante hep\u00e1tico y muerte por la enfermedad o por cualquier causa. Las probabilidades de transici\u00f3n fueron extra\u00eddas de un meta-an\u00e1lisis que re\u00fane la mejor evidencia disponible. Como desenlaces se evaluaron los a\u00f1os de vida, a\u00f1os de vida ajustados por cali-dad y costos totales. Los costos de servicios fueron extra\u00eddos de bases de datos de aseguradores colombianos, mientras que los de medicamentos fueron estimados con fuente de \u201cSistema de Informaci\u00f3n de Precios de Medicamentos\u201d. Adem\u00e1s, se utiliz\u00f3 una tasa de descuento del 5% para costos y resultados. Tambi\u00e9n, se realiz\u00f3 un an\u00e1lisis de sensibilidad tipo Montecarlo con 1000 iteraciones.\n R\nesult Ad\nos: \nLos a\u00f1os de vida ajustados por calidad (QALY) de un paciente tratado con la tec-nolog\u00eda de intervenci\u00f3n es de 11,62, mientras que con telaprevir, boceprevir y sin tratamiento es de 11,04, 10,93 y 8,93, respectivamente. Por otra parte, el costo total de un paciente tratado con daclatasvir+ asunaprevir es de $94.028.337 y los trata-\ndos con telaprevir, boceprevir y sin tratamiento son de $99.291.810, $94.786.296 y $56.950.196.\n Con\nC\nlusiones: daclastasvir+ asunaprevir, desde la perspectiva del \ntercer pagador, es una tecnolog\u00eda dominante sobre telaprevir y boceprevir, y costo-efectiva frente al no tratamiento, con una raz\u00f3n de costo efectividad incremental de $13.758.604 pesos por QALY, la cual se encuentra por debajo del umbral de tres PIB per c\u00e1pita para Colombia\nPIN20\ne\nco\nN\nom\nI\nc, Publ\nI\nc \nh\ne\nA\nlth, AN\nd \nh\num\nANI\nst\nI\nc Im\nPAct of A\n QuA\ndr\nI\nvA\nle\nN\nt \nh\num\nAN\n PAPI\nllom\nAv\nI\nrus (\nhP\nv6/11/16/18) v\nAcc\nINAt\nI\no\nN\n Progr\nA\nm for \nf\nem\nA\nles Age 9-11 Ye\nA\nrs \nIN\n \nm\nex\nI\nco\nAranda C1, Jimenez-Aranda P2, Perezbolde C3, Kulkarni AS4, Pillsbury M5, Kyle J6,  \nGuarin D7, Monsanto H8, Cashat M9\n1Hospital \u00c1ngeles del Pedregal, Morales, Mexico, 2Merck Sharp & Dohme, Mexico, Mexico, 3Merck \nSharp & Dohme, Mexico Coity, Mexico, 4Merck & Co. Inc, Rahway, NJ, USA, 5Merck & Co. Inc., \nNorth Wales, PA, USA, 6HCL America, North Wales, PA, USA, 7Merck Sharp & Dohme, Bogot\u00e1, \nColombia, 8Merck Sharp & Dohme IA LLC, Carolina, PR, PR, 9Merck Sharp & Dohme SRL de CV, \nMexico Coity, Mexico\nobjeCtives: To compare the economic, public health, and humanistic impact \nof \na quadrivalent (HPV6/11/16/18) vaccination program in a two-dose scheme \nfor 9-11 year old females with a bivalent (HPV 16/18) vaccination program in \nMexico\n Methods:\n A previously developed transmission dynamic mathematical \nmodel was adapted to evaluate the impact of routine vaccination of 9-11 year old \nbrought to you by CORE View metadata, citation and similar papers at core.ac.uk\nprovided by Elsevier - Publisher Connector A872  VALUE IN HEALTH 18 (2015) A805\u2013A881  \nobjeCtives: To assess the cost-effectiveness of simeprevir (SMV) plus peginter -\nfer\non/ribavirin (PR) versus triple therapy regimens of boceprevir (BOC)/PR and \ntelaprevir (TVR)/PR and PR dual therapy in treatment-na\u00efve and treatment-expe-\nrienced patients, chronically infected with hepatitis C virus (HCV) genotype 1, in Colombia.\n Methods:\n A lifetime Markov model, applying a generally accepted \nstructure, was used to estimate disease progression of HCV patients aged 50 years. Dosage regimens, including response-guided therapy were based on the approved labels for each product. Sustained viral response rates, were obtained from a mixed treatment comparison. Costs were estimated from health care system perspec-tive and are expressed in local currency (COP). A review of the literature to obtain epidemiologic and resource utilization data was performed and when data were not available or validation was needed a Delphi panel with local experts was car -\nried out. Primary outcomes included discounted quality adjusted life years (QALYs) and costs. Deterministic and probabilistic sensitivity analyses were performed to assess uncertainty.\n Resul\nts: Treatment-na\u00efve: In comparison with TVR/PR, BOC/\nPR and PR, SMV/PR incurred 0.133, 0.171 and 0.858 additional QALYs, respectively. SMV/PR is dominant compared to BOC/PR and TVR/PR as more total QALYs are gained and less costs accrued. The cost-effectiveness ratio of SMV/PR vs. PR is esti-mated at COP 22,984,021/QALY. Treatment experienced: In comparison with TVR/PR, BOC/PR and PR, SMV/PR increased QALYs by 0.043, 0.133 and 1.064, respectively. SMV/PR is dominant compared to BOC/PR and TVR/PR as more total QALYs are gained and less costs accrued. The cost-effectiveness ratio of SMV/PR vs. PR is esti-mated at COP 22,437,019/QALY. These results were robust in the sensitivity analy-ses.\n Co\nn\nC\nlusions: SMV/PR dominated TVR/PR and BOC/PR, and is a cost-effective \ntreatment option against WHO 3x GDP criteria in comparison to PR alone for treat-ment-na\u00efve and treatment-experienced genotype 1 HCV patients in Colombia.\nPIN27\nc\nost-\ne\nffect\nI\nve\nN\ness A\nNA\nlY\ns\nI\ns of \nsI\nme\nP\nrev\nI\nr AN\nd \ns\nofosbuv\nI\nr \nc\nomb\nINAt\nI\no\nN\n t\nher\nAPY\n for the t\nre\nAtme\nN\nt of \ng\ne\nN\not\nYP\ne 1 \nh\ncv P At\nI\ne\nN\nts \nIN\n the \nd\nom\nINI\ncAN\n \nr\ne\nP\nubl\nI\nc\nPantiri K1, Westerhout KY1, Obando CA2\n1Pharmerit International, Rotterdam, The Netherlands, 2Janssen, Panama, Panama\nobjeCtives: To assess the cost-effectiveness of simeprevir plus sofosbuvir + / - riba -\nvirin (SMV/SOF) versus sofosbuvir plus peginterferon/ribavirin (SOF/PR) and SOF/R \nregimens in treatment-na\u00efve (METAVIR F3-F4) and prior-null-responder patients (F0-F4) infected with genotype 1 HCV in the Dominican Republic (DR).\n Methods: \nA Marko\nv model, based on existing cost-effectiveness analyses, was applied to esti-\nmate disease progression of a cohort of genotype 1 HCV patients aged 47.8 years over a life time horizon. Sustained viral response (SVR) rates were obtained from the COSMOS study for SMV/SOF, from NEUTRINO for SOF/PR and from SPARE and QUANTUM for SOF/R. SVR rates for SOF/R and SOF/PR in null responder patients were conservatively assumed equal to treatment-na\u00efve patients. Patient baseline characteristics, mortality, discount rates and unit costs were obtained from local sources. HCV progression rates and health related quality of life estimates were based on literature and HCV cost-effectiveness models. Various sensitivity and scenario analyses were conducted to assess uncertainty around the estimated dis -\ncounted quality adjusted life years (QALYs) and costs.\n Resul\nts: In the treatment-\nna\u00efve patient population, SMV/SOF accrued 0.59 more QALYs and incurred $330,982 less costs per patient compared to SOF/R, resulting in SMV/SOF as the dominant treatment option. Compared to SOF/PR, SMV/SOF accrued 0.08 additional QALYs and $52,319 additional costs resulting in a cost-effectiveness ratio of $626,676 and was cost-effective against WHO 3GDP criteria. In the prior-null-responder popula-tion, SMV/SOF dominated both comparators. Multivariate probabilistic sensitivity analyses showed that at a willingness-to-pay of $1,000,000, the probability of SMV/SOF being cost-effective was estimated at 62% and 92% in the treatment-na\u00efve and prior null responder population, respectively.\n Con\nC\nlusions: SMV/SOF provides \nhigher efficacy compared to its competitors, especially for patients that are more difficult to treat (prior null responders). Compared to SOF/R and SOF/PR, SMV/SOF represents a cost-effective treatment option to treat genotype 1 HCV patients in DM.\nI\nN\nfect\nI\no\nN\n \u2013 Patient-\nr\neported \no\nutcomes & Patient Preference \ns\ntudies\nPIN28\nAvA\nl\nIA\u00e7\n\u00e3o d A\n Ades\u00e3o Ao Protocolo de t\nr\nAtA\nme\nN\nto de Pesso A\ns \nvI\nve\nN\ndo \nc\nom \nhI\nv/A\nI\nds: \nc\no\nN\nhecer \nb\nem P A\nr\nA\n \nc\nu\nI\ndA\nr \nm\nelhor\nReis HP1, Carlos JO1, Loureiro CV1, Ara\u00dajo AM1, Batista J1, Fonteles MM2\n1UFC, Fortaleza, Brazil, 2Federal University of Cear\u00e1, Fortaleza, Brazil\nobjetivos: O protocolo para HIV/AIDS do Minist\u00e9rio da Sa\u00fade brasileiro garante \nacesso uni\nversal ao tratamento para as pessoas infectadas por esse v\u00edrus (BRASIL, \n2013). Os esquemas iniciais, preferencialmente recomendados, permanecem con-stitu\u00eddos por dois inibidores de Transcriptase reversa an\u00e1logo de nucleos\u00eddeos (zidovudina+ lamivudina) e um inibidor de transcriptase reversa n\u00e3o-an\u00e1logo de \nnucleos\u00eddeos (efavirenz). Neste sentido, este trabalho, buscou determinar a ades\u00e3o dos pacientes \u00e0 primeira linha antirretroviral dessa tratativa.\n M\u00e9t\nodos: Estudo \nlongitudinal com 100 pacientes em Acompanhamento Farmacoterap\u00eautico (AFT), utilizando o M\u00e9todo D\u00e1der, atendidos em um Centro de Especialidades M\u00e9dicas em Fortaleza-CE, no per\u00edodo de novembro/2008 a agosto/2012. Os dados foram anali-sados em SPSS. Estudo aprovado pelo Comit\u00ea de \u00c9tica \u2013 Universidade Federal do Cear\u00e1 (Protocolo N\u00ba 191/08).\n Resul\ntA\ndos: Durante o AFT obteve-se m\u00e9dia de 1,41 \nesquemas/paciente, com uma mediana de 1,00; desvio padr\u00e3o de 0,79 e m\u00e1ximo de 05 mudan\u00e7as de esquemas de antirretrovirais. Na primeira linha, foram prescri-tos 15 diferentes tipos de esquemas antirretrovirais. A ades\u00e3o global ao protocolo governamental foi de 79%, sendo de 44%(44/100) a ades\u00e3o ao padr\u00e3o: (zidovudina + lamivudina) +  efavirenz, seguido do esquema alternativo envolvendo os inibi-\ndores de protease lopinavir/ritonavir agregado aos inibidores nucleos\u00eddeos da transcriptase reversa zidovudina/lamivudina, em 25% (25/100) do total na primeira escolha. Observou-se que a lamivudina esteve presente na totalidade das escolhas en el n\u00famero de casos de dengue reportados en Colombia.\n Resul\ntA\ndos: Al utilizar \ncomo referencia el criterio de la OMS para evaluar intervenciones en salud, incluy-endo en el an\u00e1lisis el efecto indirecto de la vacunaci\u00f3n y ajustando el n\u00famero de casos de dengue reportados por el subregistro, se identifica que si la vacunaci\u00f3n inicia en un periodo epid\u00e9mico \u2014desde la perspectiva del tercer pagador\u2014 el precio m\u00e1ximo por dosis para que la intervenci\u00f3n sea costo-efectiva es US$ 65,61 si la vacuna es aplicada a la poblaci\u00f3n en riesgo de nueve a\u00f1os; US$ 66,65 si se aplica en la poblaci\u00f3n entre los nueve y diecisiete a\u00f1os; y US$ 33,37 vacunando a la poblaci\u00f3n de nueve o m\u00e1s a\u00f1os.\n Con\nC\nlusiones: Estos resultados permiten identificar el precio \nm\u00e1ximo para que la intervenci\u00f3n sea costo-efectiva considerando niveles de protec-ci\u00f3n indirecta de la vacunaci\u00f3n sobre los no-vacunados y considerando el ajuste por el subregistro en el n\u00famero de casos reportados. Estos resultados representan la primera ocasi\u00f3n en que la vacuna contra el dengue de Sanofi Pasteur es evaluada a trav\u00e9s de los resultados de eficacia obtenidos en su fase III en Am\u00e9rica Latina.\nPIN24\nsI\nme\nP\nrev\nI\nr Plus Peg\nIN\nterfero\nN\n/\nrI\nbAv\nI\nr\nIN\n \nc\nost-\ne\nffect\nI\nve\nN\ness A\nNA\nlY\ns\nI\ns \nfor the t\nre\nAtme\nN\nt of \nc\nhro\nNI\nc \ng\ne\nN\not\nYP\ne 1 \nh\ne\nPAt\nI\nt\nI\ns \nc\n \nIN\n \nm\nex\nI\nco\nHeibeck M1, Westerhout KY2, Naciben V3, Gasca-Pineda R4, Hernandez-Garduno A5, \nChacon-Ramos C4\n1Pharmerit International, Berlin, Germany, 2Pharmerit International, Rotterdam, The Netherlands, \n3Janssen Pharmaceuticals, Sao Paulo, Brazi, 4Janssen Pharmaceuticals, Mexico, Mexico, 5Janssen, \nMexico City, Mexico\nobjeCtives: To assess the cost-effectiveness and cost-utility of simeprevir (SMV) \nplus pe\nginterferon/ribavirin (PR) versus boceprevir (BOC)/PR in treatment-na\u00efve \npatients [METAVIR F0-F3], versus PR in treatment-na\u00efve [F0-F3 and F4] and treat-\nment-experienced patients in partial and null responders [F0-F4], and versus \u201cno treatment\u201d in treatment-experienced patients [F0-F4], chronically infected with hepatitis C virus (HCV) genotype 1, in Mexico.\n Methods:\n A lifetime Markov \nmodel, was used to estimate disease progression for treatment-na\u00efve and treat-ment-experienced patients aged 47.8 years. Dosage regimens, including response-guided therapy and futility stopping rules, were based on Mexican HCV treatment guidelines. Sustained viral response rates were obtained from relevant phase II/III clinical trials. Patient baseline characteristics, mortality, discount rates and unit costs were obtained from local sources and an advisory board. HCV pro-gression rates and health related quality of life estimates were based on pub-lished literature and HCV cost-effectiveness models. Sensitivity analyses were conducted to estimate discounted quality adjusted life years (QALYs) and costs (in Mexican pesos).\n Resul\nts: In the treatment-na\u00efve, F0-F3 population, SMV/PR \nwas the dominant alternative, accruing more QALYs and less costs per patient compared to BOC/PR and PR alone (11.25 vs 11.08 and 10.67; $348,355 vs $455,709 and $368,416, respectively). Likewise, SMV/PR was the dominant treatment option when compared with PR alone in the treatment-na\u00efve, F4 population (7.43 vs 6.85 QALYs; $668,475 vs $731,854, respectively) and treatment-experienced (9.27 vs 8.42; $559,697 vs $609,751, respectively). Compared to \u201cno treatment\u201d, more costs and more QALYs were accumulated resulting in an incremental cost-utility ratio of $43,116 in the treatment-experienced population. Multivariate proba-bilistic sensitivity analyses showed that at a willingness-to-pay threshold of $100,000, the probability that SMV/PR is cost-effective was >\n 8\n0% for all treat -\nment groups.  Con\nC\nlusions: SMV/PR appears a cost-effective treatment option \nin genotype 1 HCV patients compared to other regimens currently available in Mexico, regardless of treatment experience and fibrosis.\nPIN25\nc\nost \ne\nffect\nI\nve\nN\ness of t\nr\nIP\nle t\nher\nAPY\n for Adults P At\nI\ne\nN\nts w\nI\nth \ng\ne\nN\not\nYP\ne 1 \nc\nhro\nNI\nc \nh\ne\nPAt\nI\nt\nI\ns \nc\nAraujo RL1, Vianna CM1, Mosegui GB2, Rodrigues MP3, Valle PM2, Felicissimo T1\n1Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2Universidade Federal \nFluminense, Niter\u00f3i, Brazil, 3UERJ, Rio de Janeiro, Rio de Janeiro, Brazil\nobjeCtives: The prevention, diagnosis and treatment of chronic hepatitis C inte-\ngr\nates health policies in Brazil and worldwide. This disease affect many people, \nfeatures high cost treatment and cause severe outcomes and disability, increasing \nsocial cost. We performed a cost-effectiveness analysis under the perspective of SUS, with the following strategies: treatment and retreatment with dual therapy, treatment with dual therapy and retreatment with triple therapy and treatment with triple therapy.\n Methods:\n A Markov model was developed with a hypotheti-\ncal cohort of 1000 adults, over 40 years, of both sexes, with confirmed diagnosis for chronic hepatitis C, monoinfected by HCV genotype 1 and absence of comorbidities.The simulation started with all individuals carrying the milder form of the disease, considered F0 or F1, according to Metavir histological classification.\n Resul\nts: \nThe results demonstrate the dual/triple therapy and triple therapy are below the acceptable threshold for embedding technology proposed by the WHO. Both are cost-effective. ICER of dual/triple therapy compared with base line was 7186.3 (R$/QALY) and the triple therapy compared with dual/triple therapy was 59053.8 (R$/QALY). However, the incremental cost of triple therapy compared to dual/triple therapy was 31029 and incremental effectiveness was 0.52. Triple therapy, despite having a little more effectiveness than the dual/triple therapy, showed much high-ercost.\n Con\nC\nlusions: Thus, as would be consistent adopt one or the other for use \nin the SUS, since this system has limited resources, is better indicate the realization a budget impact analysis to have one more data information to support the decision to continue adopting the Brazilian guideline existing or suggest making another one.\nPIN26\nsI\nme\nP\nrev\nI\nr Plus Peg\nIN\nterfero\nN\n/\nrI\nbAv\nI\nr\nIN\n \nc\nost-\ne\nffect\nI\nve\nN\ness A\nNA\nlY\ns\nI\ns \nfor the tre\nAtme\nN\nt of \nc\nhro\nNI\nc \ng\ne\nN\not\nYP\ne 1 \nh\ne\nPAt\nI\nt\nI\ns \nc\n \nIN\n \nc\nolomb\nIA\nAriza JG1, Taborda A2, Naciben V3, Heibeck M4, Westerhout KY5\n1Janssen, Bogota, Colombia, 2Johnson & Johnson, Sao Paulo-SP, Brazil, Bogota, Colombia, 3Janssen \nPharmaceuticals, Sao Paulo, Brazi, 4Pharmerit International, Berlin, Germany, 5Pharmerit \nInternational, Rotterdam, The Netherlands", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}